A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia

Connecticut-based BioXcel Therapeutics announced a win for artificial intelligence in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has approved a sublingual film drug that aims to reduce the occurrence of agitation episodes in patients diagnosed with bipolar disorder or schizophrenia. Igalmi (dexmedetomidine) is an easy-to-administer, fast-acting drug that has revived a decades-long approval stagnation in the acute treatment of schizophrenia and bipolar disorder.